Marco Romagnoli

Marco Romagnoli

Auto-generated profile, based on publicly available information

Marco Romagnoli

Department of Physical Education and Sport, University of Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2023 in Journal of Science and Medicine in Sport
Verified
Journal Article
Open access
WSWalter Staiano
Walter Staiano
SMSamuele Marcora
Samuele Marcora
MRMarco Romagnoli
Marco Romagnoli
UKUlrich Kirk
Ulrich Kirk
CRChristopher Ring
Christopher Ring
To evaluate the effects of brain endurance training (BET) on endurance and cognitive performance in road cyclists. Two independent randomized controlled pretest-posttest training studies. In both studies cyclists trained five times/week for six weeks and completed either cognitive response inhibition tasks (Post-BET group) or listened to neutral sounds (control group) after each training session. In Study-1, 26 cyclists performed a time to exhaustion (TTE) test at 80 % peak power output (PPO), followed by a 30-min Stroop task, and a TTE test at 65 % PPO. In Study-2, 24 cyclists performed a 5-min time trial, followed by a 30-min Stroop task, 60-min submaximal incremental test, and a 20-min . Heart rate, lactate, rating of perceived exertion (RPE), Stroop reaction time and accuracy were also measured. During Study 1, Post-BET improved TTE at 80 % (p = 0.032) and 65 % PPO (p = 0.011) significantly more than control with lower RPE (all p < 0.043). In Study 2, 5-min TT performance did not differ between groups. During the 60-min submaximal incremental test, RPE was lower in the Post-BET group compared to the control group (p = 0.034) and 20-min TT performance improved significantly more in the Post-BET group than in the control group (all p < 0.031). No group differences were found in physiological measures. In both studies, Stroop reaction times improved significantly more in the Post-BET group than in the control group (all p < 0.033). These findings suggest that Post-BET may be used to improve the performance of road cyclists.

23 October 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
WSWalter Staiano
Walter Staiano
CCChristine E Callahan
Christine E Callahan
MDMichelle Davis
Michelle Davis
LTLeah Tanner
Leah Tanner
SKSarah Kunkle
Sarah Kunkle
UKUlrich Kirk
Ulrich Kirk
Background: Anxiety and depressive disorders affect hundreds of millions globally, with substantial barriers limiting access to evidence-based treatments like cognitive behavioral therapy. Digital mental health interventions offer potential solutions to improve access to support. However, evidence of efficacy through randomized controlled trials is essential for clinical adoption. Objective: This study evaluated the efficacy of the Headspace Anxiety and Depression Program, a digitally delivered 21-session intervention grounded in the Unified Protocol that integrates cognitive behavioral and mindfulness-based strategies to target common drivers of emotional disorders, compared to a waitlist control group. Primary aims were to assess reductions in anxiety (Generalized Anxiety Disorder-7 [GAD-7]) and depression (Patient Health Questionnaire-8 [PHQ-8]) symptoms. Secondary aims examined improvements in sleep quality (Pittsburgh Sleep Quality Index), perceived stress (Perceived Stress Scale-10), mindfulness (Mindful Attention Awareness Scale), and overall well-being (Warwick-Edinburgh Mental Well-Being Scale), as well as clinical remission and treatment response rates. Methods: A fully remote, 2-arm parallel-group randomized controlled trial was conducted with 168 participants (aged ≥18 years) who had clinically significant anxiety (GAD-7≥10) or depression symptoms (PHQ-8≥10). Participants were randomized to either the Headspace Anxiety and Depression Program (n=84) or waitlist control (n=84). The intervention consisted of 21 daily sessions (5-10 minutes each) delivered via the Headspace app. Primary (GAD-7 and PHQ-8) and secondary outcomes (Pittsburgh Sleep Quality Index, Perceived Stress Scale-10, Mindful Attention Awareness Scale, and Warwick-Edinburgh Mental Well-Being Scale) were assessed at baseline, postintervention, and a 3-week follow-up using intention-to-treat analysis with mixed-model ANOVAs. Results: Study retention was high, with the majority (154/168, 91.7%) of participants completing the 3-week follow-up visit, and no serious adverse events were reported. Intervention adherence was high, with 82.1% (69/84) in the intervention group completing all 21 sessions. Significant group×time interactions were observed for both primary outcomes (P<.001). The Headspace group showed substantial reductions in anxiety symptoms (GAD-7: 34.5% reduction from baseline: mean 11.9, SD 2.8 to follow-up: mean 7.8, SD 2.3; η2p=0.350) and depression symptoms (PHQ-8: 33.9% reduction from baseline: mean 12.1, SD 2.8 to follow-up: mean 8.0, SD 2.0; η2p=0.370), while the control group did not show significant reductions. Combined anxiety and depression remission rates were significantly higher in the Headspace group (18/84, 21.4%) versus controls (7/84, 8.3%; P=.03), as were treatment response rates (23/84, 27.3% vs 2/84, 2.3%; P=.03). Participants in the Headspace group also demonstrated significant improvements in secondary outcomes, including sleep quality (30.2% improvement), perceived stress (13.2% reduction), mindfulness (10.3% increase), and mental well-being (10.7% increase). Conclusions: The Headspace Anxiety and Depression Program demonstrated significant efficacy in reducing anxiety and depression symptoms comparable to established treatments. Benefits were sustained at the 3-week follow-up. These findings support the potential of evidence-based transdiagnostic digital mental health interventions to address critical gaps in mental health care delivery. Trial Registration: ClinicalTrials.gov NCT06434883; https://clinicaltrials.gov/study/NCT06434883

28 June 2025 in JMIR Preprints
Verified
Preprint
Open access
WSWalter Staiano
Walter Staiano
CCChristine E Callahan
Christine E Callahan
MDMichelle Davis
Michelle Davis
LTLeah Tanner
Leah Tanner
SKSarah Kunkle
Sarah Kunkle
UKUlrich Kirk
Ulrich Kirk
BACKGROUND Anxiety and depressive disorders affect hundreds of millions globally, with substantial barriers limiting access to evidence-based treatments like cognitive behavioral therapy. Digital mental health interventions offer potential solutions to improve access to support. However, evidence of efficacy through randomized controlled trials is essential for clinical adoption. OBJECTIVE This study evaluated the efficacy of the Headspace Anxiety and Depression Program, a digitally delivered 21-session intervention grounded in the Unified Protocol that integrates cognitive behavioral and mindfulness-based strategies to target common drivers of emotional disorders, compared to a waitlist control group. Primary aims were to assess reductions in anxiety (Generalized Anxiety Disorder-7 [GAD-7]) and depression (Patient Health Questionnaire-8 [PHQ-8]) symptoms. Secondary aims examined improvements in sleep quality (Pittsburgh Sleep Quality Index), perceived stress (Perceived Stress Scale-10), mindfulness (Mindful Attention Awareness Scale), and overall well-being (Warwick-Edinburgh Mental Well-Being Scale), as well as clinical remission and treatment response rates. METHODS A fully remote, 2-arm parallel-group randomized controlled trial was conducted with 168 participants (aged ≥18 years) who had clinically significant anxiety (GAD-7≥10) or depression symptoms (PHQ-8≥10). Participants were randomized to either the Headspace Anxiety and Depression Program (n=84) or waitlist control (n=84). The intervention consisted of 21 daily sessions (5-10 minutes each) delivered via the Headspace app. Primary (GAD-7 and PHQ-8) and secondary outcomes (Pittsburgh Sleep Quality Index, Perceived Stress Scale-10, Mindful Attention Awareness Scale, and Warwick-Edinburgh Mental Well-Being Scale) were assessed at baseline, postintervention, and a 3-week follow-up using intention-to-treat analysis with mixed-model ANOVAs. RESULTS Study retention was high, with the majority (154/168, 91.7%) of participants completing the 3-week follow-up visit, and no serious adverse events were reported. Intervention adherence was high, with 82.1% (69/84) in the intervention group completing all 21 sessions. Significant group×time interactions were observed for both primary outcomes (P<.001). The Headspace group showed substantial reductions in anxiety symptoms (GAD-7: 34.5% reduction from baseline: mean 11.9, SD 2.8 to follow-up: mean 7.8, SD 2.3; η2p=0.350) and depression symptoms (PHQ-8: 33.9% reduction from baseline: mean 12.1, SD 2.8 to follow-up: mean 8.0, SD 2.0; η2p=0.370), while the control group did not show significant reductions. Combined anxiety and depression remission rates were significantly higher in the Headspace group (18/84, 21.4%) versus controls (7/84, 8.3%; P=.03), as were treatment response rates (23/84, 27.3% vs 2/84, 2.3%; P=.03). Participants in the Headspace group also demonstrated significant improvements in secondary outcomes, including sleep quality (30.2% improvement), perceived stress (13.2% reduction), mindfulness (10.3% increase), and mental well-being (10.7% increase). CONCLUSIONS The Headspace Anxiety and Depression Program demonstrated significant efficacy in reducing anxiety and depression symptoms comparable to established treatments. Benefits were sustained at the 3-week follow-up. These findings support the potential of evidence-based transdiagnostic digital mental health interventions to address critical gaps in mental health care delivery. CLINICALTRIAL ClinicalTrials.gov NCT06434883; https://clinicaltrials.gov/study/NCT06434883